EVALUATION OF VACCINATION RATES IN PATIENTS DIAGNOSED WITH COVID

Authors

  • Esra Arslan Aksu Samsun Training and Research Hospital, Department of Chest Disease, Samsun, Turkey
  • Demet Yalcin Kehribar Ondokuz Mayis University, Medical Faculty, Department of Internal Medicine, Samsun, Turkey

DOI:

https://doi.org/10.46827/ejphs.v4i2.105

Keywords:

Covid-19, pandemic, vaccine, mortality, morbidity

Abstract

The Covid-19 pandemic has caused many people to die all over the world. Isolation rules are not enough to control the epidemic, and the most important solution for returning to normal life is vaccination. In our study, data on vaccination rates and clinical courses in hospitalized patients were examined and results regarding the effectiveness of the vaccine were obtained. Vaccination rates and prognoses of patients receiving inpatient treatment with the diagnosis of Covid-19 in our pandemic clinics were investigated. 316 patients who were followed up in the clinic were examined. Among these patients, 77 (24.4%) patients were found to be vaccinated. It was determined that 239 patients (75.6%) were not vaccinated. The mean age was 41.6±5 in vaccinated patients and 24.4±4 in unvaccinated patients. While being followed in the clinic, 65 of the 78 patients who were taken to the intensive care unit were unvaccinated and 13 were vaccinated. No one died among those who were vaccinated. As a result of our study, it was determined that the vaccine reduced the rate of hospitalization significantly, similar to other studies. In addition, it has been observed that the vaccine has positive effects on the mortality and morbidity of the patients followed in the intensive care unit.

Author Biographies

  • Esra Arslan Aksu, Samsun Training and Research Hospital, Department of Chest Disease, Samsun, Turkey
    Dr. Esra Arslan Aksu is a doctor at Samsun Training and Research Hospital, Department of Chest Disease, Samsun, Turkey.
  • Demet Yalcin Kehribar, Ondokuz Mayis University, Medical Faculty, Department of Internal Medicine, Samsun, Turkey
    Ass. Prof. Demet Yalcin Kehribar is a doctor at Ondokuz Mayis University, Medical Faculty, Department of Internal Medicine, Samsun, Turkey.

References

Adams, M. L., Katz, D. L., & Grandpre, J. (2020). Population-based estimates of chronic conditions affecting risk for complications from coronavirus disease, United States. Emerging infectious diseases, 26(8), 1831.

Biggs, A. T., & Littlejohn, L. F. (2021). Revisiting the initial COVID-19 pandemic projections. The Lancet Microbe, 2(3), e91-e92

Carrillo-Vega, M. F., Salinas-Escudero, G., García-Peña, C., Gutiérrez-Robledo, L. M., & Parra-Rodríguez, L. (2020). Early estimation of the risk factors for hospitalization and mortality by COVID-19 in Mexico. PLoS One, 15(9), e0238905.

Corey, L., Mascola, J. R., Fauci, A. S., & Collins, F. S. (2020). A strategic approach to COVID-19 vaccine R&D. Science, 368(6494), 948-950.

Garg, S., Kim, L., Whitaker, M., O’Halloran, A., Cummings, C., Holstein, R., & Fry, A. (2020). Hospitalization rates and characteristics of patients hospitalized with laboratory-confirmed coronavirus disease 2019 COVID-NET, 14 States, March 1–30, 2020. Morbidity and mortality weekly report, 69(15), 458.

Hodgson, S. H., Mansatta, K., Mallett, G., Harris, V., Emary, K. R., & Pollard, A. J. (2021). What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2. The lancet infectious diseases, 21(2), e26-e35.

Voysey, M., Clemens, S. A. C., Madhi, S. A., Weckx, L. Y., Folegatti, P. M., Aley, P. K., & Bijker, E. (2021). Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. The Lancet 397(10269): 99-111.

World Health Organization. (2020). Coronavirus disease (COVID-2019) press briefings. Geneva: World Health Organization.

Downloads

Published

2021-11-26

Issue

Vol. 4 No. 2 (2021)

Section

Articles

License

Authors who publish with this journal agree to the following terms:

Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.

Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).

How to Cite

EVALUATION OF VACCINATION RATES IN PATIENTS DIAGNOSED WITH COVID. (2021). European Journal of Public Health Studies, 4(2). https://doi.org/10.46827/ejphs.v4i2.105